Respectfully disagree—the Eliquis data presented at ASH move the needle, IMO. Until now, Eliquis data in the various VTE indications have been a mixed bag, and sales projections have been based almost entirely on AF/stoke prevention. Use in a chronic VTE setting increases the addressable market substantially.
Market Data 
Markets 
AI
